Atherosclerosis Innovation Obesity 
Cardiometabolic Health Congress
JULY 25, 2024
This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease.
Cardiometabolic Health Congress
OCTOBER 25, 2024
The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.
Cardiometabolic Health Congress
DECEMBER 5, 2024
As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. View the study.
Cardiometabolic Health Congress
AUGUST 14, 2024
This October, we gather for the largest and most innovative cardiometabolic event, honoring Dr. Bakris’ profound impact on our community. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. To apply, click here or go to www.cardiometabolichealth.org/george-bakris-scholarship-program/ NEW!
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
Frontiers in Cardiovascular Medicine
FEBRUARY 18, 2025
ObjectiveMitochondrial dysfunction is associated with increased risk of atherosclerosis by disrupting key cellular processes that contribute to premature vascular ageing. EOCAD patients had lower mtDNA-CN (p<0.001) and higher mtDNA4977 deletion (p=0.026).
Cardiometabolic Health Congress
NOVEMBER 22, 2024
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. Tirzepatide’s Dual Benefits in Obesity : Recent studies on tirzepatide , a GLP-1 receptor agonist, revealed significant weight loss and improved outcomes in sleep apnea patients.
Expert insights. Personalized for you.
100 
Let's personalize your content